Partnership between Andelyn Biosciences and Grace Science to Enhance GS-100

Breakthrough Collaboration Between Grace Science and Andelyn Biosciences Brings Us One Step Closer to a Cure for NGLY1 Deficiency

Grace Science LLC and Andelyn Biosciences Inc. have recently partnered to tech transfer and manufacture GS-100, a suspension process AAV NGLY1 gene therapy for Phase I/II/III clinical trial material. This therapy is aimed at treating NGLY1 Deficiency, a serious and life-threatening disease with no approved treatment currently available. Patients with this disease experience debilitating symptoms throughout their lifetime.

The partnership between the two companies aims to maximize program efficiency, support ongoing clinical trials, and accelerate the availability of this critical therapy for patients suffering from NGLY1 Deficiency. GS-100 is a recombinant AAV9 vector that encodes the human NGLY1 gene. In 2021, GS-100 received orphan drug designation from both the FDA and the European Medicine Agency, as well as Rare Pediatric Disease Designation from the FDA.

As part of the partnership, Grace Science will benefit from Andelyn’s expertise in AAV processes and capabilities in late-stage manufacturing and commercial-readiness. This collaboration will help accelerate manufacturing timelines, bringing hope to patients in need of treatment. Matt Wilsey, CEO of Grace Science, emphasized the importance of the partnership, noting that Andelyn’s expertise in AAV gene therapy manufacturing will ensure NGLY1 patients have access to safe and high-quality drug products.

Matt Niloff, Chief Commercial Officer at Andelyn Biosciences, expressed excitement about working with Grace Science and highlighted both companies’ commitment to quality and patient-centric focus. The partnership between these two companies represents a significant step forward in bringing hope to patients with NGLY1 Deficiency who have been waiting for an effective treatment option for years.

Leave a Reply

Trump Media and Technology Group granted Nasdaq listing for multi-billion dollar wager on potential second Trump presidency Previous post Surprise Trump-DWAC Merger Values TMTG at $1.1 Billion, Igniting Interest in Digital Media Landscape”.
From Innsbruck apprentice to director of a luxury hotel in Delhi Next post A Beacon of India’s Rich History and Tourism Ambitions: The Five Star Hotel Imperial New Delhi